CMMB - Company ID 0001534248
The table below shows Chemomab Therapeutics Ltd.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2023 | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|---|
| Operating cash flow | -$7.19M | -$3.71M | -$1.29M | -$1.91M | -$3.12M |
| Capital expenditure | $1.00K | $14.00K | $3.00K | $10.00K | $75.00K |
| Investing cash flow | $14.43M | $2.38M | -$2.00K | -$10.00K | -$75.00K |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - |
Chemomab Therapeutics Ltd. reported operating cash flow of -$11.13M for fiscal year 2025. That is up 27.7% from -$15.39M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$14.22M (FY 2018) to -$11.13M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| - |
| Financing cash flow | $0.00 | $0.00 | $47.80M | $500.00K | $27.82M |